This Metastatic Colorectal Cancer (mCRC)- Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the mCRC, historical and forecasted epidemiology as well as the mCRC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The mCRC market report provides current treatment practices, emerging drugs, mCRC market share of the individual therapies, current and forecasted mCRC market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current mCRC treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032
The mCRC market report gives a thorough understanding of Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor.
CRC that spreads, or metastasizes, to the lungs, liver, or any other organ is called metastatic colorectal cancer (mCRC). The most common site of metastases for colon or rectal cancer in the liver. CRC cells may also spread to the lungs, bones, brain, or spinal cord. If a person has been treated for CRC and cancer cells have been found in these areas, it may be a sign that the original CRC has spread. mCRC is different from recurrent CRC.
Generally, most CRCs (95%) are considered sporadic, meaning the genetic changes develop by chance after a person is born, so there is no risk of passing these genetic changes on to one's children. Inherited CRCs are less common (5%) and occur when gene mutations, or changes, are passed within a family from one generation to the next. Often, the cause of CRC is not known.
Most CRCs start as a growth on the inner lining of the colon or rectum. These growths are called polyps. Some types of polyps can change into cancer over time (usually many years), but not all polyps become cancer. The chance of a polyp turning into cancer depends on the type of polyp it is.
If cancer forms in a polyp, it can grow into the wall of the colon or rectum over time. The wall of the colon and rectum is made up of many layers. CRC starts in the innermost layer (the mucosa) and can grow outward through some or all of the other layers. When cancer cells are in the wall, they can then grow into blood vessels or lymph vessels (tiny channels that carry away waste and fluid). From there, they can travel to nearby lymph nodes or distant parts of the body. The stage (extent of spread) of a CRC depends on how deeply it grows into the wall and if it has spread outside the colon or rectum.
The first and foremost step in evaluating, approximately one-fifth of CRC cases are metastatic at the time of diagnosis. Patients can present with a wide range of signs and symptoms such as occult or overt rectal bleeding, change in bowel habits, anemia, or abdominal pain. However, CRC is largely an asymptomatic disease until it reaches an advanced stage. By contrast, rectal bleeding is a common symptom of both benign and malignant causes. Therefore additional risk factors might be needed to help identify those people who should undergo further investigation by colonoscopy. New-onset rectal bleeding should generally prompt colonoscopy in individuals aged 45 years or older. In younger patients, additional factors are used to identify those at highest risk for CRC (e.g., having a family history of CRC, change in bowel habits, unexplained weight loss, and blood mixed with the stool as opposed to blood on the surface of the stool).
The goals of treatment Metastatic CRC is still an incurable disease for most of the patients, with most commonly liver, lung, or lymph nodes and peritoneal metastases. In the past, 15 years ago, median overall survival (MOS) was approximately 12 months, and the 5-year survival rate was 13%. However, the survival rate of these patients has increased, mainly due to the combined treatment of metastases with surgery and systemic therapy. Long-term survival or even cure can be attained in 20-50% of the patients who undergo complete R0 resection of liver or lung metastases, and around 70% 5-year survival of these patients can be achieved.
However, in the field of systemic therapy, there has been significant progress with new drugs in recent years. There are more options of initial systemic chemotherapy, oxaliplatin, irinotecan, and fluoropyrimidines, in combination with targeted therapy with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab, panitumumab) in case of KRAS wild type tumors or anti-vascular endothelial growth factor (VEGF) inhibitors (monoclonal antibodies bevacizumab, aflibercept, ramucirumab, regorafenib as peroral tyrosine kinase inhibitor). The combination of these novel chemotherapies and targeted therapy now extends the mOS up to 40 months.
The treatment plan may include a combination of surgery, radiation therapy, immunotherapy, and chemotherapy, which can be used to slow the spread of the disease and often temporarily shrink a cancerous tumor. Palliative care will also be important to help relieve symptoms and side effects. At this stage, surgery to remove the portion of the colon where cancer started usually cannot cure cancer, but it can help relieve the blockage of the colon or other problems related to cancer. Surgery may also be used to remove parts of other organs that contain cancer, called resection, and can cure some people if a limited amount of cancer spreads to a single organ, such as the liver or a lung. If the CRC has spread only to the liver and if surgery is possible - either before or after chemotherapy - there is a chance of complete cure. Even when curing the cancer is not possible, surgery may add months or even years to a person's life.
The mCRC epidemiology section provides insights about historical and current mCRC patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
In the year 2021, the total incident cases of mCRC were 241,115 cases in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted mCRC epidemiology [segmented as Total Incident Cases of CRC and Total incident Cases of mCRC in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides the mCRC epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The drug chapter segment of the mCRC report encloses the detailed analysis of mCRC marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the mCRC clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
The report provides the details of the emerging therapies under the late and mid-stage of development for mCRC treatment.
The mCRC market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted mCRC market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, barriers, and demand for better technology.
This segment gives a thorough detail of mCRC market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, the mCRC market in 7MM is expected to witness a major change in the study period 2019-2032.
The mCRC market size in the 7MM is expected to change during the study period 2019-2032. The therapeutic market of mCRC in the seven major markets is expected to increase during the study period (2019-2032). In 2021, the total market size of mCRC was USD 12,613.9 million which is expected to rise during the study period (2019-2032).
The total market size of mCRC in the United States accounted for USD 5,155.1 million in 2021 which is expected to rise during the study period (2019-2032).
In EU5, the total market size of mCRC was USD 4,618.5 million in 2021, which is expected to rise during the study period (2019-2032).
In Japan, the total market size of mCRC was USD 2,840.4 million in 2021, which is expected to rise during the study period (2019-2032).
This section focuses on the rate of uptake of the potential drugs recently launched in the mCRC market or expected to get launched in the market during the study period 2019-2032. The analysis covers mCRC market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses mCRC key players involved in developing targeted therapeutics.
The report covers detailed information on collaborations, acquisition, and merger, licensing patent details, and other information for mCRC emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the mCRC domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or mCRC market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
The publisher performs Competitively and Market Intelligence analysis of the mCRC Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
The mCRC market report provides current treatment practices, emerging drugs, mCRC market share of the individual therapies, current and forecasted mCRC market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current mCRC treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Metastatic Colorectal Cancer (mCRC) Understanding and Treatment Algorithm
The mCRC market report gives a thorough understanding of Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor.
CRC that spreads, or metastasizes, to the lungs, liver, or any other organ is called metastatic colorectal cancer (mCRC). The most common site of metastases for colon or rectal cancer in the liver. CRC cells may also spread to the lungs, bones, brain, or spinal cord. If a person has been treated for CRC and cancer cells have been found in these areas, it may be a sign that the original CRC has spread. mCRC is different from recurrent CRC.
Generally, most CRCs (95%) are considered sporadic, meaning the genetic changes develop by chance after a person is born, so there is no risk of passing these genetic changes on to one's children. Inherited CRCs are less common (5%) and occur when gene mutations, or changes, are passed within a family from one generation to the next. Often, the cause of CRC is not known.
Most CRCs start as a growth on the inner lining of the colon or rectum. These growths are called polyps. Some types of polyps can change into cancer over time (usually many years), but not all polyps become cancer. The chance of a polyp turning into cancer depends on the type of polyp it is.
If cancer forms in a polyp, it can grow into the wall of the colon or rectum over time. The wall of the colon and rectum is made up of many layers. CRC starts in the innermost layer (the mucosa) and can grow outward through some or all of the other layers. When cancer cells are in the wall, they can then grow into blood vessels or lymph vessels (tiny channels that carry away waste and fluid). From there, they can travel to nearby lymph nodes or distant parts of the body. The stage (extent of spread) of a CRC depends on how deeply it grows into the wall and if it has spread outside the colon or rectum.
Diagnosis
The first and foremost step in evaluating, approximately one-fifth of CRC cases are metastatic at the time of diagnosis. Patients can present with a wide range of signs and symptoms such as occult or overt rectal bleeding, change in bowel habits, anemia, or abdominal pain. However, CRC is largely an asymptomatic disease until it reaches an advanced stage. By contrast, rectal bleeding is a common symptom of both benign and malignant causes. Therefore additional risk factors might be needed to help identify those people who should undergo further investigation by colonoscopy. New-onset rectal bleeding should generally prompt colonoscopy in individuals aged 45 years or older. In younger patients, additional factors are used to identify those at highest risk for CRC (e.g., having a family history of CRC, change in bowel habits, unexplained weight loss, and blood mixed with the stool as opposed to blood on the surface of the stool).
Treatment
The goals of treatment Metastatic CRC is still an incurable disease for most of the patients, with most commonly liver, lung, or lymph nodes and peritoneal metastases. In the past, 15 years ago, median overall survival (MOS) was approximately 12 months, and the 5-year survival rate was 13%. However, the survival rate of these patients has increased, mainly due to the combined treatment of metastases with surgery and systemic therapy. Long-term survival or even cure can be attained in 20-50% of the patients who undergo complete R0 resection of liver or lung metastases, and around 70% 5-year survival of these patients can be achieved.
However, in the field of systemic therapy, there has been significant progress with new drugs in recent years. There are more options of initial systemic chemotherapy, oxaliplatin, irinotecan, and fluoropyrimidines, in combination with targeted therapy with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab, panitumumab) in case of KRAS wild type tumors or anti-vascular endothelial growth factor (VEGF) inhibitors (monoclonal antibodies bevacizumab, aflibercept, ramucirumab, regorafenib as peroral tyrosine kinase inhibitor). The combination of these novel chemotherapies and targeted therapy now extends the mOS up to 40 months.
The treatment plan may include a combination of surgery, radiation therapy, immunotherapy, and chemotherapy, which can be used to slow the spread of the disease and often temporarily shrink a cancerous tumor. Palliative care will also be important to help relieve symptoms and side effects. At this stage, surgery to remove the portion of the colon where cancer started usually cannot cure cancer, but it can help relieve the blockage of the colon or other problems related to cancer. Surgery may also be used to remove parts of other organs that contain cancer, called resection, and can cure some people if a limited amount of cancer spreads to a single organ, such as the liver or a lung. If the CRC has spread only to the liver and if surgery is possible - either before or after chemotherapy - there is a chance of complete cure. Even when curing the cancer is not possible, surgery may add months or even years to a person's life.
Metastatic Colorectal Cancer (mCRC) Epidemiology
The mCRC epidemiology section provides insights about historical and current mCRC patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
In the year 2021, the total incident cases of mCRC were 241,115 cases in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted mCRC epidemiology [segmented as Total Incident Cases of CRC and Total incident Cases of mCRC in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Metastatic Colorectal Cancer (mCRC) Epidemiology
The epidemiology segment also provides the mCRC epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Metastatic Colorectal Cancer (mCRC) Drug Chapters
The drug chapter segment of the mCRC report encloses the detailed analysis of mCRC marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the mCRC clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for mCRC treatment.
Metastatic Colorectal Cancer (mCRC) Market Outlook
The mCRC market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted mCRC market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, barriers, and demand for better technology.
This segment gives a thorough detail of mCRC market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the publisher, the mCRC market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
The mCRC market size in the 7MM is expected to change during the study period 2019-2032. The therapeutic market of mCRC in the seven major markets is expected to increase during the study period (2019-2032). In 2021, the total market size of mCRC was USD 12,613.9 million which is expected to rise during the study period (2019-2032).
The United States Market Outlook
The total market size of mCRC in the United States accounted for USD 5,155.1 million in 2021 which is expected to rise during the study period (2019-2032).
EU-5 Countries: Market Outlook
In EU5, the total market size of mCRC was USD 4,618.5 million in 2021, which is expected to rise during the study period (2019-2032).
Japan Market Outlook
In Japan, the total market size of mCRC was USD 2,840.4 million in 2021, which is expected to rise during the study period (2019-2032).
Metastatic Colorectal Cancer (mCRC) Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the mCRC market or expected to get launched in the market during the study period 2019-2032. The analysis covers mCRC market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Metastatic Colorectal Cancer (mCRC) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses mCRC key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers detailed information on collaborations, acquisition, and merger, licensing patent details, and other information for mCRC emerging therapies.
Reimbursement Scenario in Metastatic Colorectal Cancer (mCRC)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL-Views
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the mCRC domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or mCRC market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
The publisher performs Competitively and Market Intelligence analysis of the mCRC Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of mCRC, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
- Comprehensive insight has been provided into the mCRC epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for mCRC are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the mCRC market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global mCRC market
Report Highlights
- In the coming years, the mCRC market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence mCRC R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for mCRC. The launch of emerging therapies will significantly impact the mCRC market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Metastatic Colorectal Cancer (mCRC) Report Insights
- Patient Population
- Therapeutic Approaches
- mCRC Pipeline Analysis
- mCRC Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Metastatic Colorectal Cancer (mCRC) Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- mCRC Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Metastatic Colorectal Cancer (mCRC) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Questions Answered
Market Insights:
- What was the mCRC drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the mCRC total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings of the market across 7MM and which country will have the largest mCRC market size during the forecast period (2019-2032)?
- At what CAGR, the mCRC market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the mCRC market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the mCRC market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of mCRC?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical mCRC patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of mCRC in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about mCRC?
- Out of all 7MM countries, which country would have the highest prevalent population of mCRC during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the mCRC treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of mCRC in the USA, Europe, and Japan?
- What are the mCRC marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of mCRC?
- How many therapies are in-development by each company for mCRC treatment?
- How many are emerging therapies in mid-stage, and late stage of development for mCRC treatment?
- What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the mCRC therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for mCRC and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for mCRC?
- What are the global historical and forecasted markets of mCRC?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the mCRC market
- To understand the future market competition in the mCRC market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for mCRC in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the mCRC market
- To understand the future market competition in the mCRC market
Table of Contents
1. Key Insights2. Report Introduction
3. Metastatic Colorectal Cancer (mCRC) Market Overview at a Glance
3.1. Market Share (%) Distribution of mCRC in 2019
3.2. Market Share (%) Distribution of mCRC in 2032
4. Executive Summary of Metastatic Colorectal Cancer (mCRC)
4.1. Key Events
5. Epidemiology and Market Methodology
6. Disease Background and Overview
6.1. Introduction
6.2. Causes
6.3. Symptoms
6.4. CRC Staging
6.5. Risk Factors of CRC
6.6. Molecular Subtypes of CRC
6.7. Mechanisms of Metastasis in CRC
6.8. Drug Resistance in mCRC
6.9. Clinical Presentation of mCRC
6.10. Unusual Sites of Metastasis in CRC
6.10.1. Uterine Metastasis
6.10.2. Penile Metastasis
6.10.3. Scrotal Metastasis
6.10.4. Prostatic Metastasis
6.10.5. Bladder Metastasis
6.10.6. Peritoneal Pseudomyxoma
6.10.7. Abdominal Wall Metastasis
6.10.8. Bone Metastasis
6.10.9. Carcinomatous Lymphangitis
6.10.10. Adenopathies
6.10.11. Pancreatic Metastasis
6.11. Biomarkers in mCRC
6.11.1. Prognostic Biomarkers
6.11.2. Patient-Related Factors
6.11.3. Tumor-related Factors
6.11.4. Predictive Biomarkers
6.11.5. Markers to Predict 5-FU Response and Toxicity
6.11.6. Predicting Response to EGFR Therapy
6.11.7. Predicting Response to VEGF Inhibitors
6.11.8. Technology-Facilitated Biomarkers
6.12. Diagnosis
6.12.1. Clinical symptoms
6.12.2. Endoscopy
6.12.3. Imaging
6.12.4. Laboratory
6.12.5. Pathology
6.12.6. Biopsy
6.12.7. Molecular Testing of the Tumor
6.12.8. Blood Tests
6.12.9. Tumor-based Tests
6.12.10. Diagnosis of colorectal liver metastasis
7. Recognized Establishments
8. Treatment of Metastatic Colorectal Cancer (mCRC)
8.1. Initial/First-line Treatment of mCRC
8.2. Second and Third-line Treatment of mCRC
8.3. Therapies using medication
8.4. Surgery
8.5. Adjuvant therapy
8.6. Follow-up
8.7. Palliation
8.8. Maintenance Therapy
8.9. Treatment of Colon Cancer That Has Metastasized to a Single Site
9. Treatment of Patients with Late-stage Colorectal Cancer: ASCO Resource-Stratified Guideline (2020)
10. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer (2016)
10.1. Recommendations
10.1.1. Recommendation 1: Tissue handling
10.1.2. Recommendation 2: A selection of specimens for biomarker testing
10.1.3. Recommendation 3: Tissue selection
10.1.4. Recommendation 4: RAS testing
10.1.5. Recommendation 5: BRAF testing
10.1.6. Recommendation 6: MSI testing
10.1.7. Recommendation 7: Biomarkers of chemotherapy sensitivity and toxicity
10.1.8. Recommendation 8: Emerging biomarkers not recommended for routine patient management outside of a clinical trial setting
10.1.9. Recommendation 9: Emerging technologies
10.1.10. Recommendation 10: OMD
10.1.11. Recommendation 11: Imaging in the identification and management of disease
10.1.12. Recommendation 12: Perioperative treatment
10.1.13. Recommendation 13: Conversion therapy
10.1.14. Recommendation 14: Ablative techniques
10.1.15. Recommendation 15: Local ablation techniques
10.1.16. Recommendation 16: Embolization
10.1.17. Recommendation 17: Cytoreductive surgery and HIPEC
10.1.18. Recommendation 18: First-line systemic therapy combinations according to the targeted agent used
10.1.19. Recommendation 19: Maintenance therapy
10.1.20. Recommendation 20: Second-line combinations with targeted agents
10.1.21. Recommendation 21: Third-line therapy
10.2. Consensus recommendations on the use of cytotoxics and biologicals in the first- and subsequent-line treatment of patients with mCRC
10.2.1. Consensus recommendation for patients where cytoreduction with 'conversion' and/or the integration of local ablative treatment is the goal
10.2.2. Consensus recommendation for patients where cytoreduction is needed because of aggressive biology and/or risk of developing or existing severe symptoms
10.2.3. Consensus recommendation for patients where disease control is the goal
11. National Institute for Health and Care Excellence (NICE) Guidelines: Colorectal Cancer (2020)
11.1. Management of metastatic disease
11.1.1. People with asymptomatic primary tumor
11.1.2. People with mCRC in the liver
11.1.3. People with metastatic colorectal cancer in the lung
11.1.4. People with metastatic colorectal cancer in the peritoneum
11.2. Ongoing care and support
11.2.1. Follow-up for detection of local recurrence and distant metastases
12. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM) (2016)
12.1. Metastatic CRC Treatment Recommendations
12.1.1. Evaluation of elderly patients
12.1.2. Surgery for advanced disease
12.1.3. Locoregional treatments
13. Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)
13.1. Recommendations on palliative chemotherapy indication for older patients with mCRC
13.2. Recommendations for cytotoxic chemotherapy in older patients:
13.3. Anti-angiogenic recommendations for older:
13.4. Recommendations for anti-EGFR, regorafenib and trifluridinetipiracil in older patients:
14. Spanish Society of Medical Oncology (SEOM) clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
15. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines for the treatment of colorectal cancer- 2019
15.1. Treatment strategies for Stage IV CRC
15.2. Treatment strategies for hematogenous metastases
15.2.1. Treatment strategies for liver metastases
15.2.2. Treatment strategies for brain metastases
15.2.3. Treatment strategies for hematogenous metastases to other organs
16. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Colon and Rectal Cancer (2021)
17. Epidemiology and Patient Population
17.1. Key Findings
17.2. Epidemiology of Metastatic Colorectal Cancer (mCRC)
17.3. Epidemiology Scenario
17.3.1. Total Incident Cases of Colorectal Cancer (CRC)
17.3.2. Total Incident Cases of Metastatic Colorectal Cancer (mCRC)
18. Patient Journey
19. Key Endpoints in Metastatic Colorectal Cancer (mCRC)
20. Marketed Therapies
20.1. Key Cross
20.2. Keytruda (pembrolizumab): Merck
20.2.1. Drug Description
20.2.2. Regulatory Milestones
20.2.3. Other Developmental Activities
20.2.4. Pivotal Clinical Trial
20.2.5. Ongoing Current Pipeline Activity
20.2.6. Safety and Efficacy
20.3. Stivarga (Regorafenib): Alexion Pharmaceuticals
20.3.1. Drug Description
20.3.2. Regulatory Milestones
20.3.3. Other Developmental Activities
20.3.4. Pivotal Clinical Trial
20.3.5. Ongoing Current Pipeline Activity
20.3.6. Safety and Efficacy
20.4. Jemperli (dostarlimab): GlaxoSmithKline (GSK)
20.4.1. Drug Description
20.4.2. Regulatory Milestones
20.4.3. Pivotal Clinical Trial
20.5. Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib): Array BioPharma/ Pfizer + Pfizer
20.5.1. Drug Description
20.5.2. Regulatory Milestones
20.5.3. Other Developmental Activities
20.5.4. Pivotal Clinical Trial
20.5.5. Ongoing Current Pipeline Activity
20.5.6. Safety and Efficacy
20.6. Cyramza (ramucirumab): Eli Lilly
20.6.1. Drug Description
20.6.2. Regulatory Milestones
20.6.3. Other Developmental Activities
20.6.4. Pivotal Clinical Trial
20.6.5. Ongoing Current Pipeline Activity
20.6.6. Safety and Efficacy
20.7. Lonsurf (TAS-102): Taiho Oncology
20.7.1. Drug Description
20.7.2. Regulatory Milestones
20.7.3. Other Developmental Activities
20.7.4. Pivotal Clinical Trial
20.7.5. Ongoing Current Pipeline Activity
20.7.6. Safety and Efficacy
20.8. Opdivo (nivolumab) + Yervoy (ipilimumab): Bristol-Myers Squibb
20.8.1. Drug Description
20.8.2. Regulatory Milestones
20.8.3. Pivotal Clinical Trial
20.8.4. Ongoing Current Pipeline Activity
20.8.5. Safety and Efficacy
20.9. Vectibix (panitumumab) + Folfox/Chemotherapy: Amgen
20.9.1. Drug Description
20.9.2. Regulatory Milestones
20.9.3. Other Developmental Activities
20.9.4. Pivotal Clinical Trial
20.9.5. Ongoing Current Pipeline Activity
21. Emerging Therapies
21.1. Key Cross
21.2. Adagrasib (MRTX849) + cetuximab: Mirati Therapeutics + Merck
21.2.1. Product Description
21.2.2. Other Development Activities
21.2.3. Clinical Development
21.2.4. Safety and Efficacy
21.3. MK-4280A (favezelimab and pembrolizumab): Merck
21.3.1. Product Description
21.3.2. Other Development Activities
21.3.3. Clinical Development
21.3.4. Safety and Efficacy
21.4. Lynparza (olaparib) ± bevacizumab: Merck
21.4.1. Product Description
21.4.2. Other Development Activities
21.4.3. Clinical Development
21.5. Elunate (fruquintinib/HMPL-013): Hutchison Medipharma
21.5.1. Product Description
21.5.2. Other Development Activities
21.5.3. Clinical Development
21.5.4. Safety and Efficacy
21.6. Corsela (trilaciclib): G1 Therapeutics
21.6.1. Product Description
21.6.2. Other Development Activities
21.6.3. Clinical Development
21.7. Lenvima (lenvatinib/MK-7902/E7080) + Keytruda (pembrolizumab): Merck/Eisai
21.7.1. Product Description
21.7.2. Other Development Activities
21.7.3. Clinical Development
21.7.4. Safety and Efficacy
21.8. Modufolin (arfolitixorin): Isofol Medical
21.8.1. Product Description
21.8.2. Other Development Activities
21.8.3. Clinical Development
21.8.4. Safety and Efficacy
21.9. Lumakras (sotorasib) + Vectibix (panitumumab): Amgen
21.9.1. Product Description
21.9.2. Other Development Activities
21.9.3. Clinical Development
21.9.4. Safety and Efficacy
21.10. Masitinib: AB Science
21.10.1. Product Description
21.10.2. Other Development Activities
21.10.3. Clinical Development
21.11. Numidargistat (INCB001158): Incyte Corporation
21.11.1. Product Description
21.11.2. Other Development Activities
21.11.3. Clinical Development
21.11.4. Safety and Efficacy
21.12. Enhertu (trastuzumab deruxtecan): Daiichi Sankyo/AstraZeneca
21.12.1. Product Description
21.12.2. Other Development Activities
21.12.3. Clinical Development
21.12.4. Safety and Efficacy
21.13. Keytruda (pembrolizumab) + ibrutinib: Merck/Janssen
21.13.1. Product Description
21.13.2. Other Development Activities
21.13.3. Clinical Development
21.13.4. Safety and Efficacy
21.14. Onvansertib: Cardiff oncology
21.14.1. Product Description
21.14.2. Other Development Activities
21.14.3. Clinical Development
21.14.4. Safety and Efficacy
21.15. RRx-001: EpicentRx
21.15.1. Product Description
21.15.2. Clinical Development
21.15.3. Safety and Efficacy
21.16. Lenvima (lenvatinib) + pembrolizumab: Merck/Eisai
21.16.1. Product Description
21.16.2. Other Development Activities
21.16.3. Clinical Development
21.16.4. Safety and Efficacy
21.17. Tukysa (tucatinib) ± Herceptin (trastuzumab): Seagen + Roche
21.17.1. Product Description
21.17.2. Other Development Activities
21.17.3. Clinical Development
21.17.4. Safety and Efficacy
21.18. NT-17/GX-I7 (efineptakin Alfa) + Keytruda (pembrolizumab): NeoImmuneTech (Genexine) + Merck
21.18.1. Product Description
21.18.2. Other Development Activities
21.18.3. Clinical Development
21.18.4. Safety and Efficacy
21.19. BDTX-189: Black Diamond Therapeutics
21.19.1. Product Description
21.19.2. Other Development Activities
21.19.3. Clinical Development
21.20. Magrolimab + Erbitux (cetuximab): Gilead Sciences + Eli Lilly and Company
21.20.1. Product Description
21.20.2. Other Development Activities
21.20.3. Clinical Development
21.20.4. Safety and Efficacy
21.21. ONCOS-102 + IMFINZI (durvalumab): Ludwig Institute for Cancer Research + Targovax ASA
21.21.1. Product Description
21.21.2. Other Development Activities
21.21.3. Clinical Development
21.21.4. Safety and Efficacy
22. Metastatic Colorectal Cancer (mCRC): 7 Major Market Analysis
22.1. Key Findings
22.2. Market Outlook
22.2.1. Prescription Pattern Analysis
22.2.2. Emerging Drugs Analysis
22.3. Market Size of Metastatic Colorectal Cancer
22.3.1. Total Market Size of Metastatic Colorectal Cancer (mCRC)
22.3.2. Market Size of Metastatic Colorectal Cancer (mCRC) by Therapies
23. Market Access and Reimbursement
24. KOL Views
25. Market Drivers
26. Market Barriers
27. SWOT Analysis
28. Unmet Needs
29. Appendix
29.1. Bibliography
29.2. Report Methodology
30. Publisher Capabilities
31. Disclaimer
32. About the Publisher
List of Tables
Table 1: Summary of Metastatic Colorectal Cancer, Market, Epidemiology, and Key Events (2019-2032)
Table 2: AJCC Staging for CRC
Table 3: Prognostic factors in mCRC
Table 4: Predictive factors for targeted therapies in mCRC
Table 5: The list of biomarkers used in the clinical practice of mCRC
Table 6: Recognized Establishments
Table 7: Percentage of patients that are prescribed different lines of treatment for mCRC
Table 8: Recommendations on Diagnosis
Table 9: Recommendations on Staging
Table 10: First-Line Treatment
Table 11: Recommendations on Second-Line Systemic Colorectal Metastatic Treatment
Table 12: Recommendations on Third-Line and Fourth-Line Systemic Colorectal Metastatic Treatment
Table 13: Recommendations on Liver-Directed Therapies in Patients with mCRC
Table 14: Summary Treatment Options for Late-Stage CRC
Table 15: Recommendations on Surveillance/Follow-up
Table 16: mCRC: SIGN recommendations
Table 17: mCRC treatment: GRADE recommendations
Table 18: Evaluation of elderly patients: SIGN recommendations
Table 19: Surgery: SIGN recommendations
Table 20: Liver-directed therapies: SIGN recommendations
Table 21: Non-liver-directed therapies: SIGN recommendations
Table 22: Recommendations for diagnosis and treatment of mCRC
Table 23: Total Incident Cases of Metastatic Colorectal Cancer (CRC) in the 7MM (2019-2032)
Table 24: Total Incident Cases of Metastatic Colorectal Cancer (mCRC) in the 7MM (2019-2032)
Table 25: Key cross of marketed drugs for mCRC
Table 26: Dosing Recommendations in mCRC Patients
Table 27: Patent Expiration
Table 28: Keytruda (pembrolizumab), Clinical Trial Description, 2021
Table 29: Patent Expiration
Table 30: Stivarga (Regorafenib), Clinical Trial Description, 2021
Table 31: Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib), Clinical Trial Description, 2021
Table 32: Ramucirumab, Clinical Trial Description, 2021
Table 33: Lonsurf, Clinical Trial Description, 2021
Table 34: Nivolumab + Ipilimumab, Clinical Trial Description, 2021
Table 35: FOLFIRI + Panitumumab, Clinical Trial Description, 2021
Table 36: Drug Key Cross of emerging drugs under development for mCRC
Table 37: Adagrasib (MRTX849) + cetuximab, Clinical Trial Description, 2021
Table 38: MK-4280A, Clinical Trial Description, 2021
Table 39: Olaparib ± Bevacizumab, Clinical Trial Description, 2021
Table 40: Elunate (fruquintinib/HMPL-013), Clinical Trial Description, 2021
Table 41: Trilaciclib, Clinical Trial Description, 2021
Table 42: Lenvima (lenvatinib)+ Keytruda (pembrolizumab), Clinical Trial Description, 2021
Table 43: Modufolin (arfolitixorin), Clinical Trial Description, 2021
Table 44: Lumakras (sotorasib) + Vectibix (panitumumab), Clinical Trial Description, 2021
Table 45: Masitinib, Clinical Trial Description, 2021
Table 46: Numidargistat (INCB001158) + gemcitabine/cisplatin, Clinical Trial Description, 2021
Table 47: Enhertu (trastuzumab deruxtecan), Clinical Trial Description, 2021
Table 48: Pembrolizumab + Ibrutinib, Clinical Trial Description, 2021
Table 49: Onvansertib, Clinical Trial Description, 2021
Table 50: RRx-001, Clinical Trial Description, 2021
Table 51: Lenvima (lenvatinib) + pembrolizumab, Clinical Trial Description, 2021
Table 52: Tucatinib ± Trastuzumab, Clinical Trial Description, 2021
Table 53: NT-17/GX-I7 (efineptakin Alfa) + Keytruda (pembrolizumab), Clinical Trial Description, 2021
Table 54: BDTX-189, Clinical Trial Description, 2021
Table 55: Magrolimab + Erbitux (cetuximab), Clinical Trial Description, 2021
Table 56: ONCOS-102 + IMFINZI (durvalumab), Clinical Trial Description, 2021
Table 57: 7MM Market Size of Metastatic Colorectal Cancer in USD Million (2019-2032)
Table 58: 7MM Market Size of Metastatic Colorectal Cancer (mCRC) by Therapies in USD Million (2019-2032)List of Figures
Figure 1: Epidemiology and Market Methodology
Figure 2: Mechanisms of metastasis in CRC- hematogenous versus peritoneal spread
Figure 3: Current and emerging biomarkers used in personalizing treatment for patients with mCRC
Figure 4: EGFR signaling pathway with potential predictive markers
Figure 5: VEGF signaling pathway
Figure 6: NCCN Guidelines for Colon Cancer
Figure 7: NCCN Guidelines for the treatment of Rectal Cancer
Figure 8: Total Incident Cases of CRC in the 7MM (2019-2032)
Figure 9: Total Incident Cases of mCRC in the 7MM (2019-2032)
Figure 10: Market Size of mCRC in the 7MM, USD Million (2019-2032)
Figure 11:7MM Market Size of mCRC by Therapies in USD Million (2019-2032)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB Science
- Alexion Pharmaceuticals
- Amgen
- Array BioPharma
- AstraZeneca
- Black Diamond Therapeutics
- Bristol-Myers Squibb
- Cardiff oncology
- Daiichi Sankyo
- Eisai
- Eli Lilly
- EpicentRx
- G1 Therapeutics
- Gilead Sciences
- GlaxoSmithKline (GSK)
- Hutchison Medipharma
- Incyte Corporation
- Isofol Medical
- Janssen
- Ludwig Institute for Cancer Research
- Merck
- Mirati Therapeutics
- NeoImmuneTech (Genexine)
- Pfizer
- Roche
- Seagen
- Taiho Oncology
- Targovax ASA
